∇ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. LONDON, Dec. 2, 2025 /PRNewswire/ -- Accord Healthcare today announced the launch ...

(RTTNews) - Fresenius (FRE.DE) announced the launch of its denosumab biosimilars, Conexxence and Bomyntra, in Europe. The biosimilars received approval from the European Commission in July 2025 for ...

Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA ...

TEL AVIV, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced that the European ...

Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced the US Food and Drug ...

The FDA has approved two new drugs that are biosimilars to denosumab, adding to the ever-expanding field of less expensive options of the popular anti-osteoporosis and cancer-related bone loss drug; ...

Findings showed denosumab-kyqq demonstrated similar quality, safety, and efficacy to the reference product. Bosaya is approved to treat postmenopausal women with osteoporosis at high risk for fracture ...

Credit: Celltrion. The denosumab biosimilars Stoboclo and Osenvelt have the same indications as the reference products Prolia and Xgeva, respectively. Patient support and financial assistance are ...

Among patients with severe postmenopausal osteoporosis unresponsive to long-term denosumab, addition of romosozumab improved lumbar spine bone mineral density. Denosumab combined with romosozumab may ...

Complex organizational problems and chaos are silent killers of productivity and innovation. In today’s fractured work environment, they are more prevalent than ever. Political transitions, ...

The Food and Drug Administration has approved Fresenius Kabi's Biologics License Application for the denosumab biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht). These denosumab ...